u/Disappointing_Truth

I think Daiichi Sankyo might be slept on. Their new Enhertu drug is clearly outperforming regular chemo and is being recommended all over the world. Astra Zeneca as a partner. Trading at their 52 week low. They have their earnings although delayed on the 11th. They also have another variant of Enhertu pending FDA approval and polymarket has predicted it will pass with 80% probability. If on the 11th they present a solid earnings forward guidance, I think it might move quite heavily

No positions yet, waiting for regard input. But possibly 5k in short time shares.

edit: mispelled Daiichi